NYSE:OGN
Organon & Co. Stock News
$21.80
+0.280 (+1.30%)
At Close: May 17, 2024
New Strong Sell Stocks for August 8th
08:17am, Monday, 08'th Aug 2022
COWN, AUD, and OGN have been added to the Zacks Rank #5 (Strong Sell) List on August 8, 2022.
Organon & Co. (OGN) CEO Kevin Ali on Q2 2022 Results - Earnings Call Transcript
01:04pm, Thursday, 04'th Aug 2022
Organon & Co. (NYSE:OGN ) Q2 2022 Earnings Conference Call August 4, 2022 8:30 AM ET Company Participants Jennifer Halchak - Vice President, Investor Relations Kevin Ali - Chief Executive Officer Matt
Organon To Report Second Quarter Results and Host Conference Call on August 4, 2022
07:30am, Thursday, 21'st Jul 2022
JERSEY CITY, N.J.--(BUSINESS WIRE)-- #organon--Organon will release its second quarter 2022 financial results on 8/4/22, prior to the company's webcast and call scheduled for 8:30 a.m. EDT.
Organon Vs. Viatris: Who Is The Clear Winner?
09:23pm, Sunday, 19'th Jun 2022
Organon's P/E ratio was 6.5 at the end of Q1 2022, significantly lower than the pharmaceutical industry average. Viatris' revenue was $4,191.7 million in the first quarter of 2022, down 5.4% from a ye
Organon: Maximum Optimism
01:04pm, Thursday, 28'th Apr 2022
Biosimilar sales were $118 million in Q4 2021, up 14.6% from Q4 2020. Organon's dividend yield is around 3.5%, which is one of the largest in the pharmaceutical industry.
Why Organon (OGN) is Poised to Beat Earnings Estimates Again
01:32pm, Monday, 25'th Apr 2022
Organon (OGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?
10:20am, Friday, 15'th Apr 2022 Zacks Investment Research
Sector ETF report for XPH
Organon Inks Licensing Pact For Daré Bioscience's Bacterial Vaginosis Treatment
01:33pm, Thursday, 31'st Mar 2022
Organon & Co (NYSE: OGN) will license global rights to Daré Bioscience Inc's (NASDAQ: DARE) Xaciato (clindamycin phosphate vaginal gel, 2%). Xaciato is an FDA-approved medication for treating
3 of the Best Value Stocks to Buy Heading Into April
03:07pm, Wednesday, 30'th Mar 2022 The Motley Fool
With these shares at modest valuations, you can score some cheap long-term investments.
Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?
10:20am, Tuesday, 29'th Mar 2022 Zacks Investment Research
Smart Beta ETF report for XPH
Organon supports fight against heart disease in Filipinos
12:17pm, Thursday, 10'th Mar 2022 BusinessMirror
Do you know your lipid profile? High cholesterol usually has no signs or symptoms. The only way to…
Organon & Co. (OGN) CEO Kevin Ali Presents at 42nd Annual Cowen Health Care Conference (Transcript)
03:51pm, Wednesday, 09'th Mar 2022 Seeking AlphaOrganon & Co. (OGN) CEO Kevin Ali Presents at 42nd Annual Cowen Health Care Conference (Transcript)
10:51am, Wednesday, 09'th Mar 2022
Organon & Co. (OGN) CEO Kevin Ali Presents at 42nd Annual Cowen Health Care Conference (Transcript)
New Upgrade: Organon & Co Stock Shows Rising Relative Strength
06:12pm, Wednesday, 02'nd Mar 2022 Investor''s Business Daily
Organon & Co sees its Relative Strength Rating enter the elite 90-plus level.
Organon To Present at the Cowen 42nd Annual Healthcare Virtual Conference
12:00pm, Wednesday, 02'nd Mar 2022 Business Wire
JERSEY CITY, N.J.--(BUSINESS WIRE)-- #Health--Organon (NYSE: OGN), announced today that Kevin Ali, Chief Executive Officer, and Matthew Walsh, Chief Financial Officer, are scheduled to participate in a fireside chat at the Cowen 42nd Annual Healthcare Virtual Conference on Wednesday, March 9, 2022 at 9:10 a.m. EST. Investors, analysts, members of the media and the general public are invited to watch to a live video webcast of the presentation at https://www.organon.com/investor-relations/events-and-prese
